InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,617.63
(
0.04%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.85
(
-0.02%
)
Bitcoin
62,437.90
(
0.17%
)
Post# of 48316
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Titan V

Send PM Follow Ignore
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Titan V

Re: Titan V post# 39121

Friday, 04/28/2017 10:57:01 AM

Friday, April 28, 2017 10:57:01 AM

Post# of 48316
So they're going to be using Keytruda to treat Keytruda AND Opdivo non-responders. Imagine the value of this treatment if successful, from Merck's perspective, being able to treat a rival's non-responders.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ONCSQ News
More ONCSQ News
InvestorsHub NewsWire

FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Start posting your company's news
Only $200 per official company press release!